propagermanium has been researched along with Cerebral Ischemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, W; Fang, W; He, S; Huang, L; Li, B; Li, Y; Liu, R; Miyata, M; Tembachako, CR; Xiong, X; Xu, B; Zheng, X | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Oshima, K; Tsukuda, K | 1 |
2 other study(ies) available for propagermanium and Cerebral Ischemia
| Article | Year |
|---|---|
Propagermanium, a CCR2 inhibitor, attenuates cerebral ischemia/reperfusion injury through inhibiting inflammatory response induced by microglia.
Topics: Animals; Brain Ischemia; Cell Line; Germanium; Inflammation Mediators; Male; Mice; Mice, Inbred C57BL; Microglia; Organometallic Compounds; Propionates; Random Allocation; Receptors, CCR2; Reperfusion Injury | 2019 |
Irbesartan attenuates ischemic brain damage by inhibition of MCP-1/CCR2 signaling pathway beyond AT₁ receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Brain Ischemia; Germanium; Irbesartan; Losartan; Male; Mice; Mice, Inbred C57BL; Organometallic Compounds; Propionates; Receptors, CCR2; Signal Transduction; Tetrazoles | 2011 |